Avanir Pharmaceuticals
 Home  About  Investors  Product R&D  Employment  Contact

AVANIR PHARMACEUTICALS is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases.

AVANIR'S products and product candidates address therapeutic markets that include central nervous system disorders, inflammation, and infectious disease.

Avanir Producs

Approved Products

product indicator abreva® (docosanol 10% cream)

Investigational Products

product indicator Zenvia™ for PBA
product indicator MIF Inhibitor
product indicator Zenvia™ for Diabetic Peripheral Neuropathic Pain

product indicator Zenvia™ for Pseudobulbar Affect (PBA)

Learn more about the Star Trial clinical study that is now underway.

Webcasts

8th Annual Needham Life Sciences Conference
Date: Jun 11, 2009
Begins: 9:00 a.m. ET

Deutsche Bank 34th Annual Health Care Conference
Date: May 19, 2009
Begins: 1:15 p.m. ET

Latest News

Jun 29, 2009
AVANIR Pharmaceuticals Announces It Has Been Added to the Russell 3000® Index

Jun 04, 2009
AVANIR to Present at the Needham Life Sciences Conference

Jun 03, 2009
AVANIR Regains Compliance with NASDAQ Listing Requirements

Home | About | Investors | Products | Employment | Contact
© 2002 Avanir Disclosure